论文部分内容阅读
目的:观察伍用纳络酮治疗中、重度新生儿HIE的疗效及治疗前后患儿血浆及脑脊液中β-内啡肽（β-EP）的变化。方法:将40例HIE患儿随机分为两组:纳络酮治疗组23例,对照组17例,两组除进行相同的常规治疗外,治疗组给纳络酮0.1mg/kg·d,以0.03～0.05mg/kg·h速度静滴,连续3天,观察患儿临床症状体征的变化并进行NBNA评分,治疗前后分别留取患儿血浆和脑脊液测定β-EP,并与20名正常儿对照。结果:治疗组患儿临床症状明显改善,NBNA评分明显提高,与对照组相比差异显著;两组患儿治疗前血浆和脑脊液中β-EP明显高于正常新生儿,治疗后较治疗前显著下降,但治疗组与对照组治疗前后血浆和脑脊液β-EP含量均无统计学差异。结论:伍用纳络酮治疗中重度HIE临床疗效显著。
Objective: To observe the effect of Naloxone on neonates with moderate and severe neonates and the changes of β-EP in plasma and cerebrospinal fluid of children before and after treatment. Methods: Forty children with HIE were randomly divided into two groups: naloxone treatment group (n = 23) and control group (n = 17). In addition to the same routine treatment, the two groups were given naloxone 0.1 mg / kg · d, The rats were treated with 0.03 ~ 0.05mg / kg · h for 3 consecutive days. The changes of clinical symptoms and signs were observed and the NBNA scores were recorded. The plasma and cerebrospinal fluid were collected before and after treatment. Β-EP was measured and compared with 20 normal Children control. Results: The clinical symptoms of the treatment group were significantly improved, NBNA score was significantly increased, compared with the control group, the difference was significant. The β-EP in plasma and cerebrospinal fluid of the two groups before treatment was significantly higher than that of the normal neonates, But there was no significant difference in β-EP content in plasma and cerebrospinal fluid between treatment group and control group before and after treatment. Conclusion: The clinical efficacy of Naloxone in the treatment of moderate-severe HIE is significant.